APA (7th ed.) Citation

JS, L., KJ, H., SA, I., KW, L., S, P., JS, T., . . . MG, K. (2026). Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC. British journal of cancer, 134(11), 1568. https://doi.org/10.1038/s41416-026-03408-y

Chicago Style (17th ed.) Citation

JS, Lopez, et al. "Phase 1 Study of Ceralasertib, an ATR Kinase Inhibitor, in Combination with Durvalumab in Patients with Recurrent or Metastatic NSCLC or HNSCC." British Journal of Cancer 134, no. 11 (2026): 1568. https://doi.org/10.1038/s41416-026-03408-y.

MLA (9th ed.) Citation

JS, Lopez, et al. "Phase 1 Study of Ceralasertib, an ATR Kinase Inhibitor, in Combination with Durvalumab in Patients with Recurrent or Metastatic NSCLC or HNSCC." British Journal of Cancer, vol. 134, no. 11, 2026, p. 1568, https://doi.org/10.1038/s41416-026-03408-y.